Mirae Asset Global Investments’s Puma Biotechnology PBYI Stock Holding History

Mirae Asset Global Investments’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.5K	Sell	2,276 -378	-14%	-$2.77K	﹤0.01%	1500
2026 Q1	$17K	Buy	2,654 +205	+8%	+$1.32K	﹤0.01%	1451
2025 Q4	$14.6K	Buy	+2,449	New	+$13K	﹤0.01%	1578
2015 Q3	–	Sell	-13,700	Closed	-$1.6M	–	471
2015 Q2	$1.6M	Buy	13,700 +4,600	+51%	+$833K	0.05%	240
2015 Q1	$2.15M	Buy	9,100 +4,733	+108%	+$1.01M	0.07%	195
2014 Q4	$826K	Buy	+4,367	New	+$969K	0.03%	292

Other funds holding PBYI

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mirae Asset Global Investments's PBYI Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Puma Biotechnology (PBYI) stake by 14% in Q2 2026, selling an estimated $2.77K and leaving 2,276 shares worth $18.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1500.

Mirae Asset Global Investments first reported a position in PBYI in Q4 2014 and has held it in 6 quarters since. The position peaked at $2.15M in Q1 2015. 160 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

Mirae Asset Global Investments held 2,276 shares of Puma Biotechnology worth $18.5K as of Q2 2026.
Mirae Asset Global Investments sold 378 Puma Biotechnology shares in Q2 2026, an estimated $2.77K.
Puma Biotechnology made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1500 holding.
Mirae Asset Global Investments first reported a position in Puma Biotechnology in Q4 2014 and has held it in 6 quarters since.
Mirae Asset Global Investments's Puma Biotechnology position peaked at $2.15M in Q1 2015.
160 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.